These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 7818593

  • 1. Activity of 4-quinolones against Pseudomonas aeruginosa.
    Morissey I, Smith JT.
    Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593
    [Abstract] [Full Text] [Related]

  • 2. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
    Parte AC, Smith JT.
    Microbios; 1994 Oct; 80(322):31-9. PubMed ID: 7854197
    [Abstract] [Full Text] [Related]

  • 3. Influence of temperature on mutational resistance to 4-quinolones.
    Parte AC, Smith JT.
    Arzneimittelforschung; 1996 Apr; 46(4):429-32. PubMed ID: 8740093
    [Abstract] [Full Text] [Related]

  • 4. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH, Vostrov SN, Alferova IV, Lubenko IY, Portnoy YA, Firsov AA.
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
    Garrison MW.
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V, Messina C, Santagati M, Campanile F, Bonfiglio G, Stefani S.
    Drugs Exp Clin Res; 2001 Jan; 27(3):107-11. PubMed ID: 11447768
    [Abstract] [Full Text] [Related]

  • 7. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, Dworkin RJ, Slaughter SE, Leggett JE.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y, Ozaki M, Matsuda M, Honmura T, Nishimura I, Yamaguchi R, Adachi T, Okawa Y, Nishino T.
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [Abstract] [Full Text] [Related]

  • 9. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL, Fuchs PC, Brown SD.
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [Abstract] [Full Text] [Related]

  • 10. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
    Seral C, Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
    Wagenlehner FM, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG.
    Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
    MacGowan AP, Wootton M, Holt HA.
    J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
    [Abstract] [Full Text] [Related]

  • 15. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G, Puech C, Lucht F, Loboguerrero M, Denis M, Dorche G.
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [Abstract] [Full Text] [Related]

  • 16. Mutation rates to 4-quinolone resistance.
    Smith JT.
    Arzneimittelforschung; 1990 Jan; 40(1):65-8. PubMed ID: 2111135
    [Abstract] [Full Text] [Related]

  • 17. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa.
    Segatore B, Setacci D, Perilli M, Franceschini N, Marchetti F, Amicosante G.
    Int J Antimicrob Agents; 2000 Jan; 13(3):223-6. PubMed ID: 10724029
    [Abstract] [Full Text] [Related]

  • 18. The bactericidal effect on Pseudomonas strains of adriamycin associated with quinolones.
    Castelli M, Baggio G, Aresca P, Bossa R, Galatulas I.
    Anticancer Res; 1989 Jan; 9(3):611-4. PubMed ID: 2504105
    [Abstract] [Full Text] [Related]

  • 19. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
    Flynn CM, Johnson DM, Jones RN.
    J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM, Mazzucco CE, Lawrence LE, Ho H, Warr G, Barrett JF, Frosco M.
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.